The new business unit aims to lead antimicrobial stewardship in India with innovative solutions covering 3000 hospitals and healthcare institutions over the next two to three years

Chennai-based Orchid Pharma announced the formation of Orchid AMS (Antimicrobial Solutions), a dedicated division focussed on helping address the critical challenge of Antimicrobial Resistance (AMR) in India. The strategic move aims to address the growing threat of Antimicrobial Resistance (AMR) in India and globally through innovative products, comprehensive support programs, and digital solutions.

Orchid AMS will spearhead the company’s efforts to combat AMR through a comprehensive approach encompassing innovative product development, robust support programmes, and advanced digital solutions. The new entity aims to partner with over 2,500-3,000 hospitals and healthcare institutions in the next two to three years, to implement effective antimicrobial stewardship programs (AMSPs).

Manish Dhanuka, MD, Orchid Pharma, said, “The launch of Orchid AMS is proof of our commitment to addressing the urgent public health threat posed by AMR. By combining our expertise in antimicrobials and our US FDA-approved manufacturing capabilities, we aim to make a significant impact on combating this public health crisis in India and beyond, said Manish Dhanuka, Managing Director of Orchid Pharma.

Rajnish Rohatgi, CEO, Orchid AMS added, “Orchid AMS invites leading pharmaceutical companies to join us in this task – to collaborate, even while we compete – and work with healthcare providers, policymakers, and other stakeholders to develop and implement effective strategies to combat this growing threat.”